Working… Menu

Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma (TemAvIr)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01022918
Recruitment Status : Completed
First Posted : December 1, 2009
Last Update Posted : September 25, 2012
National Cancer Institute, France
Association de Neuro-Oncologues d'Expression Francaise
Hoffmann-La Roche
Information provided by (Responsible Party):
Centre Georges Francois Leclerc

Brief Summary:

Treatment of glioblastoma (GBM) is based on surgery when possible, and chemoradiation with temozolomide, which became a standard since the EORTC study (Stupp, 2005). However, the prognosis of unresectable GBM remains poor despite chemoradiation with an estimated 10 month median survival, in the range of the comparable patients in the RPA class V from the EORTC study (Miramanoff, 2006).

Vredenburgh et al. from the Duke University (Durham, NC) reported at ASCO 2006 (fully published in J Clin Oncol, 2007) a 57 % unexpected response rate using a bevacizumab/irinotecan schedule in patients with relapsed GBM or grade 3 astrocytomas. This unusual high response rate, sometimes with major and sustained responses, was confirmed by a cooperative french study of ANOCEF (Guiu et al., 2008). Such a major improvement of treatment effectiveness lead ANOCEF, which federates most of the active neuro-oncology teams in France, to propose a neo-adjuvant and adjuvant bevacizumab-based chemotherapy framing a standard temozolomide-based chemoradiation with the aim to improve the prognosis of unresectable GBM.

The bevacizumab/temozolomide combination as neo-adjuvant is presently being evaluated by the Duke University. We believe that an ambitious comparison of the bevacizumab/irinotecan-schedule with the ''standard'' temozolomide-based chemoradiation is a fascinating challenge to improve the treatment of this awful disease.

The ANOCEF proposal '' Evaluation of the irinotecan/bevacizumab association as neo-adjuvant and adjuvant treatment of chemoradiation with temozolomide for naive unresectable glioblastoma. Phase II randomized study with comparison to chemoradiation with temozolomide'' has been successfully granted by INCA (Institut National du Fancer, France) through its research program ( PHRC : Programme Hospitalier de Recherche Clinique). Implementation of this program is now starting .

Condition or disease Intervention/treatment Phase
Naive Unresectable Glioblastoma Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures) Drug: Temodal/radiotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 134 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide
Study Start Date : January 2009
Actual Primary Completion Date : July 2010
Actual Study Completion Date : January 2011

Arm Intervention/treatment
Experimental: Bevacizumab/Irinoecan

Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.

Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).

Adjuvant treatment:

Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks.

Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)
Active Comparator: Stupp
patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
Drug: Temodal/radiotherapy

Primary Outcome Measures :
  1. To determine the rate of non-progressive disease at 6 months after inclusion in each arms [ Time Frame: after half of each arms has been completed at 6 months of treatment ]

Secondary Outcome Measures :
  1. To determine if bevacizumab-based regimen increases the overall survival in comparison of the Stupp regimen [ Time Frame: december 2011 ]
  2. To evaluate if any bevacizumab-based regimen increases the survival without neurologic degradation and the quality of life according to the QLC-C30 and the specific Brain Cancer Module QLQ-BN20 scales. [ Time Frame: december 2011 ]
  3. To evaluate the tolerance of the bevacizumab-based regimens according to the NCI-CTCAE, version 3.0 scale. To record the rate of serious adverse events (mainly the theoretical risk of brain hemorrhage with bevacizumab) [ Time Frame: december 2011 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All the eligibility criteria must be met before registration :

  • delay upper or equal to 14 days from stereotaxic biopsy and 28 days from surgical biopsy
  • Histopathologically proven diagnosis of glioblastoma (WHO grade IV astrocytoma)
  • Patient belonging to the RPA V class or associated
  • only supratentorial glioblastoma
  • Diagnosis must be obtained by a stereotactic or surgical biopsy
  • Age between 18 and 70
  • A contrast-enhanced MRI must be performed within 28 days prior to study registration
  • Total or partial surgical resection deemed as not possible by a neurosurgeon
  • Karnofsky Index (KI) performance status over 50
  • Life expectancy of at least 3 months
  • A stable dose of corticosteroid for at least 7 days to control intracranial pressure and neurological symptoms
  • Adequate blood function : absolute neutrophil count > 1.5 x 109/L, platelets count > 100 x 109/L platelets; hemoglobin > 10 g/dl after blood transfusion if required
  • Adequate liver function: bilirubin < 1.5 ULN (upper limit of normal), ALT and AST < 2.5 ULN, Prothrombin rate > 75 %
  • Adequate renal function: creatinine < 1.2 ULN; proteinuria test 0 or trace (or urine protein concentration < 1g/24h if proteinuria test is + or ++).
  • Negative pregnancy test for women of childbearing potential and adequate contraception for men and women.
  • systolic arterial blood pressure at rest ≤ 170 mmHg
  • Patient must have been informed and must have signed the specific informed consent form.
  • holder of a coverage by the health insurance

Exclusion Criteria:

  • patient belonging to the RPA III or IV
  • prior malignant tumor in the recent 5 years or concomitant malignancy
  • prior anti-tumoral chemotherapy or radiotherapy
  • prior gross resection of the brain tumor
  • patient receiving gliadel
  • cardiovascular contra-indications to bevacizumab : prior angina pectoris, prior myocardial infarction, prior brain stroke, even transient, distal severe arteriopathy, uncontrolled high blood pressure
  • anticomitial drug p450 cytochrome inductors
  • other substances inducing p450 cytochrome
  • proteinuria ≥ 1g/L
  • concurrent anticoagulant or platelet anti-aggregant treatment
  • congenital haemorrhagic pathology (haemophilia, Willebrandt)
  • sign of brain haemorrhage on the RMI initial exam
  • non resolved infectious disease
  • non controlled arterial hypertension (≥170 mmHg)
  • intracranial high pressure not controlled by a stable dose of steroids for at least 7 days
  • pregnancy or refusal of the contraception for women and men
  • psychiatric, behavioural disorders or geographical situation precluding the administration or follow-up of the protocol (including claustrophobia)
  • digestive haemorrhage and / or gastro-duodenal ulcer occurring in the last 3 months
  • pregnant, nursing woman, or without contraception
  • private individuals of freedom or under tutelage (including legal guardianship)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01022918

Layout table for location information
Centre Georges François Leclerc
Dijon, Bourgogne, France, 21000
Sponsors and Collaborators
Centre Georges Francois Leclerc
National Cancer Institute, France
Association de Neuro-Oncologues d'Expression Francaise
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Bruno Chauffert, Professor Centre Hospitalier Universitaire, Amiens
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre Georges Francois Leclerc Identifier: NCT01022918    
Other Study ID Numbers: TemAvIr
First Posted: December 1, 2009    Key Record Dates
Last Update Posted: September 25, 2012
Last Verified: September 2012
Keywords provided by Centre Georges Francois Leclerc:
unresectable glioblastoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action